SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JOEBT1 who wrote (1177)12/13/2005 11:59:30 AM
From: Icebrg   of 2240
 
Joe

I don't think there was too much to comment upon. Evidently BMY is pushing very hard to roll out MDX-010 covering as much territory as possible. The decision to widen the registration trials to cover all types of first- and second line indications in multiple myeloma, without waiting for the current registration trial to reach its conclusion, is very aggressive.

But ever since Pfizer paid that huge amount up-front for the "cross-licensing" deal, I have felt pretty convinced, that the drug should have a very good chance of making it all the way.

MDX-060, MDX-070 and MDX-214 seem all to be dead - at least in their present incarnations. I am not surprised as there hasn't been any positive news on any of these drugs for a long, long time.

All in all, Medarex looks pretty solid now. Let's just hope that they continue to peel away the less promising drugs from the pipe-line. With MDX-010 becoming a potential blockbuster there is little need for marginal drugs to be developed.

As Medarex intends to keep the employment at current levels, I don't think there are any major expansion plans. In order to be able to bring in one or two new drugs into the pipeline each year something has to give at the other end to make place.

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News